Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1
7(70.0%)
Phase 2
3(30.0%)
10Total
Phase 1(7)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT02846571Phase 1Recruiting

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

Role: collaborator

NCT02586831Phase 1Withdrawn

Diabetes Islet Preservation Immune Treatment

Role: collaborator

NCT03406897Phase 1Completed

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

Role: collaborator

NCT02213003Phase 1Completed

Allogeneic Islet Cells Transplanted Onto the Omentum

Role: collaborator

NCT03444064Phase 1Completed

PolyTreg Immunotherapy in Islet Transplantation

Role: collaborator

NCT00306098Phase 2Completed

Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression

Role: collaborator

NCT03243058Phase 1Withdrawn

Low-dose IL-2 in Established T1D - The "PROREG" Study

Role: collaborator

NCT01786707Phase 1Completed

Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus

Role: collaborator

NCT00315588Phase 2Completed

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Role: collaborator

NCT00315614Phase 2Terminated

Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus

Role: collaborator

All 10 trials loaded